Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma

23Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

Aim: To investigate the relationship between loss of heterozygosity (LOH) for mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/ IGF2R) and the outcomes for primary HCC patients treated with partial hepatectomy. Methods: The LOH for M6P/IGF2R in primary HCC patients was assessed using six different gene-specific nucleotide polymorphisms. The patients studied were enrolled to undergo partial hepatectomy. Results: M6P/IGF2R was found to be polymorphic in 73.3% (22/30) of the patients, and of these patients, 50.0% (11/22) had tumors showing LOH in M6P/IGF2R. Loss of heterozygosity in M6P/IGF2R was associated with significant reductions in the two year overall survival rate (24.9% vs 65.5%; P = 0.04) and the disease-free survival rate (17.8% vs 59.3%; P = 0.03). Conclusion: These results show M6P/IGF2R LOH predicts poor clinical outcomes in surgically resected primary HCC patients. © 2008 WJG. All rights reserved.

Cite

CITATION STYLE

APA

Jang, H. S., Kang, K. M., Choi, B. O., Chai, G. Y., Hong, S. C., Ha, W. S., & Jirtle, R. L. (2008). Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma. World Journal of Gastroenterology, 14(9), 1394–1398. https://doi.org/10.3748/wjg.14.1394

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free